about
Use of metformin in the setting of mild-to-moderate renal insufficiencyEffect of Cephalexin on the Pharmacokinetics of Metformin in Healthy Human VolunteersAdult metformin ingestions reported to Texas poison control centers, 2000-2006Contraindications to the use of metforminRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusClinically and pharmacologically relevant interactions of antidiabetic drugsUse of metformin in diseases of agingMetformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the EndotheliumSafety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitusRenal drug transporters and their significance in drug-drug interactionsMetformin and the gastrointestinal tractEffect of altered gastric emptying and gastrointestinal motility on metformin absorptionUnderstanding and overcoming metformin gastrointestinal intolerance.Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Effect of prescribing metformin according to eGFR instead of serum creatinine level: A study based on Korean National Health and Nutrition Examination Survey (KNHANES) 2009-2014.In situ forming formulation: development, evaluation, and optimization using 3(3) factorial design.AMPK activation--protean potential for boosting healthspan.Influence of Plantago ovata husk (dietary fiber) on the bioavailability and other pharmacokinetic parameters of metformin in diabetic rabbitsMetformin in peritoneal dialysis: a pilot experienceAcute Effect of Metformin on Postprandial Hypertriglyceridemia through Delayed Gastric EmptyingEstablishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations.Pharmacokinetics of metformin during pregnancy.Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendationsEffects of exercise training on mitochondrial function in patients with type 2 diabetes.Metformin selectively attenuates mitochondrial H2O2 emission without affecting respiratory capacity in skeletal muscle of obese ratsThe Association between 25-Hydroxyvitamin D and Hemoglobin A1c Levels in Patients with Type 2 Diabetes and Stage 1-5 Chronic Kidney Disease.The effect of metformin treatment in vivo on acute and long-term energy metabolism and progesterone production in vitro by granulosa cells from women with polycystic ovary syndromeEffect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2.First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis.Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes.Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium.Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis.Gestational diabetes mellitus management with oral hypoglycemic agents.Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes.Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes.Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin.Pharmacokinetic strategies in deciphering atypical drug absorption profiles.The metabolic state of cancer stem cells-a valid target for cancer therapy?
P2860
Q22241290-DCF383F6-0A82-4726-AD06-CFE4790A6C89Q22241384-F8E93C76-809B-41E1-B43C-E9AE3C4E9662Q22241808-63B813D9-C7BC-4752-BDF3-466EC6701BF5Q22242091-294BD26E-E036-4FD3-B948-E4A80B46BBB8Q24235718-F35FA47A-FFE6-4A29-86EA-558A8172C751Q24240522-EE2EE917-A33D-4589-ACFF-99C9E307AC73Q26752468-F36CB6CC-1EE5-4B7C-8EEF-BFDB19C01CF8Q26828760-50B0D86C-03FB-4098-8A9D-D331731B6339Q26999344-FB673A5C-DEEB-4E56-8192-D802E7FDCAECQ27027877-1439C67F-0A68-4663-AFD5-17FBA0BD0B7CQ28071292-FCF5BCD2-5719-4AB9-8D0A-90A163A12907Q28079250-AD8CD8EF-C1A0-41F1-B730-AD346164B19FQ28344811-EA668DAF-2187-428F-A326-9A7A9263F0A1Q30240030-E321BCED-186B-4D69-8C22-8C6856E1BE4FQ30249371-36EF71E5-37B0-48AF-B154-26F2209D7758Q33554434-3503DA30-1E08-4D25-ABBD-577A6A5955B4Q33573509-F963E63D-A580-4C26-817D-DB002EFE6D50Q33689169-4B804088-8A4A-4403-BBEE-B2CAC5057C89Q33776193-D8885872-F382-4D96-A921-E18FECB6310CQ33837650-2A8225AA-991B-4781-BE31-4C0D84138DC9Q33839003-1EBD58D2-76A4-4726-AC24-CB7361E744E8Q33845157-4F7AC08C-27EC-4B43-B88A-FCD0BA4BC495Q33861891-303F88DA-D6F2-4D7D-83D8-DD67116003ACQ33873111-DCD5A997-0670-4552-ADD4-23B78E5F9994Q34023559-ADB70A31-55A9-4A2B-B7B5-1D154351648BQ34065151-8C1C4583-9561-446A-BFA4-2405036146BFQ34176759-EBE1A4B3-6E83-4F93-AA29-AB695552C130Q34181502-229DCF02-A996-4025-928D-9D5028105863Q34292544-90975BC9-6EB1-43F5-909F-E68DFB937A1EQ34356103-3EB4312E-8135-47D8-A631-057E90C27812Q34421386-7E5B3306-F555-4ADE-B252-52FE82829C39Q34429278-147629C9-1144-4CA7-9C2A-17B6BA567A1DQ34505650-F138FECA-F28F-41C0-8DBF-1CD2929A2AB6Q34573001-DE00E831-4CC9-47C2-B2CD-5CAC74B0AB1CQ34616656-D4119830-C5BD-40F7-9BEA-EE752884F576Q34620565-FB4A5BEB-A8F8-40A6-8FD6-B3F4031CC1BDQ34620693-269D15EE-EEAF-444F-87E2-11ECE5881469Q35014972-64F43A33-A360-47E9-AA6A-9DC852390A66Q35085676-17A5D7AD-C3FE-47E3-AA8F-1FDA3C0A3833Q35118801-E62ACC6E-FB1B-4F94-B552-48AB831771FB
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Clinical pharmacokinetics of metformin.
@en
type
label
Clinical pharmacokinetics of metformin.
@en
prefLabel
Clinical pharmacokinetics of metformin.
@en
P1476
Clinical pharmacokinetics of metformin.
@en
P2093
A J Scheen
P304
P356
10.2165/00003088-199630050-00003
P577
1996-05-01T00:00:00Z
P6179
1033547440